View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsDICE Therapeutics 将来の成長Future 基準チェック /06現在、 DICE Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報-22.3%収益成長率-14.78%EPS成長率Pharmaceuticals 収益成長14.4%収益成長率86.8%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日09 Aug 2023今後の成長に関する最新情報Price Target Changed • Jun 21Price target decreased by 13% to US$56.30Down from US$64.43, the current price target is an average from 10 analysts. New target price is 21% above last closing price of US$46.44. Stock is up 217% over the past year. The company is forecast to post a net loss per share of US$2.57 next year compared to a net loss per share of US$2.13 last year.すべての更新を表示Recent updatesお知らせ • Aug 10+ 1 more updateEli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders.Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders for $2.3 billion on June 18, 2023. Pursuant to the agreement, Eli Lilly and Company will commence a cash tender offer to purchase all of the outstanding shares of common stock of DICE Therapeutics at a price of $48 per share, net to the seller in cash, without interest, and subject to applicable withholding taxes. Following the successful closing of the tender offer, Lilly will acquire any shares of DICE that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Upon termination of the agreement under specified circumstances DICE Therapeutics may be required to pay Eli Lilly and Company a termination fee of $92 million. As of July 25, 2023, Eli Lilly and Company announced the extension of the expiration of the tender offer from one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Lilly that, as of 4:30 p.m., Eastern time, on July 24, 2023, approximately 9,581,902 Shares have been validly tendered and not properly withdrawn in the tender offer, representing approximately 20.05% of the issued and outstanding Shares, as of such date and time. Holders that have previously tendered their Shares do not need to re-tender their Shares or take any other action in response to the extension of the tender offer. Consummation of the offer is subject to various conditions, including a majority of Shares then-outstanding being tendered in the offer and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The consummation of the Offer and Merger is not subject to a financing condition. The Board of Directors of DICE Therapeutics unanimously approved the transaction. The Board of Directors of Eli Lilly and Company approved the transaction. Offer commenced on June 30, 2023 and is initially scheduled to expire on July 28, 2023. The transaction is expected to close in the third quarter of 2023. Michael P. Brueck, Chelsea N. Darnell, Daniel Yip and Monica Ruiz of Kirkland & Ellis LLP acted as legal advisor to Eli Lilly and Company. Matthew Rossiter, Douglas N. Cogen and David K. Michaels of Fenwick & West LLP acted as legal advisor to DICE Therapeutics. For DICE, Centerview Partners LLC is acting as exclusive financial advisor and fairness opinion provider. DICE has agreed to pay Centerview an aggregate fee of approximately $44 million, $2 million of which was payable upon the rendering of Centerview’s opinion and approximately $42 million of which is payable contingent upon consummation of the Transactions. Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to Centerview in the transaction. Kirkland & Ellis LLP acted as due diligence provider to Lilly. Centerview Partners LLC acted as due diligence provider to DICE. Equiniti Trust Company acted transfer agent to DICE. Julia L. Minitti, Michael Hostetler and Uale Taotafa of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisors to DICE. Eli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders on August 9, 2023. DICE's common stock will be delisted from the NASDAQ Global Market.お知らせ • Jun 21Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion.Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion on June 18, 2023. Pursuant to the agreement, Eli Lilly and Company will commence a cash tender offer to purchase all of the outstanding shares of common stock of DICE Therapeutics at a price of $48 per share, net to the seller in cash, without interest, and subject to applicable withholding taxes. Following the successful closing of the tender offer, Lilly will acquire any shares of DICE that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Upon termination of the agreement under specified circumstances DICE Therapeutics may be required to pay Eli Lilly and Company a termination fee of $92 million. Consummation of the offer is subject to various conditions, including a majority of Shares then-outstanding being tendered in the offer and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The consummation of the Offer and Merger is not subject to a financing condition. The Board of Directors of DICE Therapeutics unanimously approved the transaction. The Board of Directors of Eli Lilly and Company approved the transaction. The transaction is expected to close in the third quarter of 2023. Michael P. Brueck and Chelsea N. Darnell of Kirkland & Ellis LLP acted as legal advisor to Eli Lilly and Company. Matthew Rossiter, Douglas N. Cogen and David K. Michaels of Fenwick & West LLP acted as legal advisor to DICE Therapeutics. For DICE, Centerview Partners LLC is acting as exclusive financial advisor and fairness opinion provider.New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$231m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (25% increase in shares outstanding).Price Target Changed • Jun 21Price target decreased by 13% to US$56.30Down from US$64.43, the current price target is an average from 10 analysts. New target price is 21% above last closing price of US$46.44. Stock is up 217% over the past year. The company is forecast to post a net loss per share of US$2.57 next year compared to a net loss per share of US$2.13 last year.分析記事 • May 14We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, DICE Therapeutics...Recent Insider Transactions • Mar 22Independent Director recently sold US$291k worth of stockOn the 17th of March, James Scopa sold around 10k shares on-market at roughly US$29.05 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • Feb 11DICE Therapeutics, Inc. Announces Board ChangesOn February 7, 2023, Shaan Gandhi, M.D., D. Phil., notified the Board of Directors of DICE Therapeutics, Inc. of his intent to resign as a Class I director of the Board, as the chair of the Nominating and Corporate Governance Committee of the Board and as a member of the Audit Committee of the Board, effective February 10, 2023. Such Resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company. In addition, the Board appointed Dr. Jake Simson, an existing member of the Board, to serve on the Audit Committee, effective upon the Resignation.Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Mittie Doyle was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 12DICE Therapeutics, Inc. Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for PsoriasisDICE Therapeutics, Inc. announced positive topline data from its Phase 1 clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17. The trial was a first-in-human, randomized, double-blind, placebo-controlled study designed to generate safety and pharmacokinetic (PK) data in healthy volunteers as well as provide early clinical proof-of-concept in psoriasis patients. The trial was conducted in three overlapping parts: Phase 1a single ascending dose (SAD) (n=40); Phase 1b multiple ascending dose (MAD) (n=32); and Phase 1c proof-of-concept in psoriasis patients (n=32). Proof-of-concept achieved, supporting further development of DC-806 as potential best-in-class oral agent for psoriasis: The Phase 1c, placebo-controlled psoriasis portion enrolled a total of 8 patients in the high dose group (800 mg BID), 13 patients in the low dose group (200 mg BID), and 11 patients in the placebo group. Following 4 weeks of treatment, the mean percentage reduction in Psoriasis Area and Severity Index (PASI) from baseline was 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008. Reduction in PASI was an exploratory endpoint with no correction for multiplicity. Both doses of DC-806 shown to be biologically active via analysis of well-precedented biomarkers: Exploratory biomarker data demonstrated dose-dependent IL-17 target engagement, rapid onset of action, and pharmacodynamic effects consistent with direct inhibition of IL-17 signaling. DC-806 was well tolerated with an excellent safety profile across all dose groups: Data across all three cohorts showed DC-806 was well tolerated with a favorable safety profile in both healthy volunteers and psoriasis patients at all dose levels evaluated with no serious adverse events, no dose-limiting adverse events, no treatment-related discontinuations, and no clinically-significant changes in clinical and safety lab parameters (including liver enzymes). All treatment emergent adverse events (TEAEs) were classified as mild or moderate with no dose-dependent trend in the frequency, severity, or type of TEAEs observed. Robust PK profile and dose-dependent IL-17 target coverage: DC-806 showed a favorable PK profile with dose-proportional increases in serum concentrations throughout the study. Analysis of the MAD and Phase 1c data showed achievement of IC50 and IC90 coverage at trough with doses of 175 mg QD and 400 mg BID, respectively. DICE plans to advance DC-806 into a dose-ranging Phase 2b clinical trial in patients with moderate-to-severe psoriasis. The company plans to submit an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) in the first half of 2023 and initiate Phase 2b development.Seeking Alpha • Oct 11DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higherTop-line results from a phase 1 trial of DICE Therapeutics' (NASDAQ:DICE) DC-806 for psoriasis showed the candidate met its proof-of-concept goal and was biologically active. Shares are up 71% in premarket trading. Data also showed DC-806 was well tolerated with an excellent safety profile. The placebo-controlled portion enrolled eight psoriasis patients in the high dose group (800 mg BID), 13 patients in the low dose group (200 mg BID), and 11 patients in the placebo group. After four weeks of treatment, the mean percentage reduction in Psoriasis Area and Severity Index from baseline was 43.7% in the high dose group compared to 13.3% in the placebo group. DICE (DICE) now plans to move DC-806, an oral IL-17 antagonist, into a dose-ranging phase 2b clinical trial. The company anticipates submitting an IND application with the US FDA in 1H 2023 and begin phase 2b at that time. Seeking Alpha's Quant Rating views DICE as a hold with high marks for growth and momentum.分析記事 • Sep 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 11DICE Therapeutics GAAP EPS of -$0.58DICE Therapeutics press release (NASDAQ:DICE): Q2 GAAP EPS of -$0.58. Cash, cash equivalents and marketable securities totaled $282.2 million at June 30, 2022. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milestones.お知らせ • Jul 22DICE Therapeutics, Inc. Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806DICE Therapeutics, Inc. announced the completion of enrollment in the Company’s Phase 1 clinical trial of DC-806 in healthy volunteers and psoriasis patients. DC-806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of autoimmune and inflammatory diseases, including psoriasis. The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to generate safety and pharmacokinetic data and provide early clinical proof-of-concept in psoriasis patients. The trial is being conducted in three overlapping parts: Phase 1a (single ascending dose) and Phase 1b (multiple ascending dose) in healthy volunteers, and a Phase 1c (proof-of-concept) in psoriasis patients.Seeking Alpha • Jul 18DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugsHC Wainwright has initiated coverage of DICE Therapeutics (NASDAQ:DICE) with a buy rating lauding the company's DELSCAPE technology platform aimed at creating new therapies against "difficult to target protein-protein interactions (PPIs), using small, targeted DNA-enabling libraries (DELs)." The firm has a $40 price target (~151% upside based on Friday's close). Analyst Emily Bodnar said that DELSCAPE can "identify selective binders by producing small, targeted DELs which has led to hundreds to tens of thousands of hits against difficult PPI targets." The company's lead candidate DC-806, a pill that targets IL-17, is being eyed for psoriasis. It is currently in phase 1. Bodnar conceded that although there are several IL-17-targeted biologics for psoriasis and related indications, there is only one approved that is a pill, Amgen's (AMGN) Otezla (apremilast). She noted that though Otezla has a PASI-75 score (efficacy) of only ~30%, the drug has more than $2B in annual sales. A full data readout from the phase 1 trial is expected this quarter, and if it is positive, the stock could see significant upside, Bodnar wrote.お知らせ • Jun 26+ 1 more updateDICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 2000 Growth IndexDICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 2000 Growth IndexBoard Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mittie Doyle was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 05High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mittie Doyle was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 29DICE Therapeutics, Inc. Expands Management Team and Board of DirectorsDICE Therapeutics, Inc. announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE’s board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company’s board. Mary Riley, J.D., as general counsel: Ms. Riley joins DICE following a 15-year tenure at Genentech, most recently serving as vice president, litigation, where she served on the legal leadership team and was responsible for managing a wide range of legal matters. She also previously led Genentech’s business law group and employment law group, where she served as a member of the human resources leadership team. Before joining Genentech, Mary was a partner at Heller Ehrman LLP and held roles at other corporate law firms. Mary received a J.D. Lisa Bowers, MHSA, to board of directors: Ms. Bowers is the chief commercial officer of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company founded to address a critical unmet need, the lack of therapeutic development in pediatric cancer. Prior to joining Day One, Lisa served as the chief executive officer and founder of Rhia Ventures. Mittie Doyle, M.D., FACR, to board of directors: Dr. Doyle is a proven research physician who has held numerous leadership roles in clinical development. She currently serves as chief medical officer of Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines. Prior to joining Aro, Dr. Doyle served as vice president, global therapeutic area head, immunology at CSL Behring.Reported Earnings • Nov 15Third quarter 2021 earnings released: US$2.30 loss per shareThird quarter 2021 results: Net loss: US$17.3m (flat on 3Q 2020).お知らせ • Sep 15DICE Therapeutics, Inc. has completed an IPO in the amount of $204 million.DICE Therapeutics, Inc. has completed an IPO in the amount of $204 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $17 Transaction Features: Sponsor Backed Offering業績と収益の成長予測NasdaqGM:DICE - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-224-161-205812/31/2024N/A-169-161-155912/31/2023N/A-140-116-10996/30/2023N/A-104-87-84N/A3/31/2023N/A-91-75-73N/A12/31/2022N/A-84-67-64N/A9/30/2022N/A-77-63-61N/A6/30/2022N/A-74-56-54N/A3/31/20221-59-46-45N/A12/31/20211-49-40-39N/A9/30/20211-40-31-30N/A6/30/20212-29-27-27N/A3/31/20211-27-24-24N/A12/31/20201-24-21-21N/A12/31/20196-13-17-16N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: DICE今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: DICE今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: DICE今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: DICE来年は収益がないと予測されています。高い収益成長: DICE来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: DICEの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/10 16:21終値2023/08/08 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DICE Therapeutics, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Jason Matthew GerberryBofA Global ResearchEdward NashCanaccord GenuityPrakhar AgrawalCantor Fitzgerald & Co.9 その他のアナリストを表示
Price Target Changed • Jun 21Price target decreased by 13% to US$56.30Down from US$64.43, the current price target is an average from 10 analysts. New target price is 21% above last closing price of US$46.44. Stock is up 217% over the past year. The company is forecast to post a net loss per share of US$2.57 next year compared to a net loss per share of US$2.13 last year.
お知らせ • Aug 10+ 1 more updateEli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders.Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders for $2.3 billion on June 18, 2023. Pursuant to the agreement, Eli Lilly and Company will commence a cash tender offer to purchase all of the outstanding shares of common stock of DICE Therapeutics at a price of $48 per share, net to the seller in cash, without interest, and subject to applicable withholding taxes. Following the successful closing of the tender offer, Lilly will acquire any shares of DICE that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Upon termination of the agreement under specified circumstances DICE Therapeutics may be required to pay Eli Lilly and Company a termination fee of $92 million. As of July 25, 2023, Eli Lilly and Company announced the extension of the expiration of the tender offer from one minute past 11:59 p.m., Eastern time, on July 28, 2023, has been extended until one minute past 11:59 p.m., Eastern time, on Aug. 8, 2023, unless the tender offer is further extended or earlier terminated. Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Lilly that, as of 4:30 p.m., Eastern time, on July 24, 2023, approximately 9,581,902 Shares have been validly tendered and not properly withdrawn in the tender offer, representing approximately 20.05% of the issued and outstanding Shares, as of such date and time. Holders that have previously tendered their Shares do not need to re-tender their Shares or take any other action in response to the extension of the tender offer. Consummation of the offer is subject to various conditions, including a majority of Shares then-outstanding being tendered in the offer and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The consummation of the Offer and Merger is not subject to a financing condition. The Board of Directors of DICE Therapeutics unanimously approved the transaction. The Board of Directors of Eli Lilly and Company approved the transaction. Offer commenced on June 30, 2023 and is initially scheduled to expire on July 28, 2023. The transaction is expected to close in the third quarter of 2023. Michael P. Brueck, Chelsea N. Darnell, Daniel Yip and Monica Ruiz of Kirkland & Ellis LLP acted as legal advisor to Eli Lilly and Company. Matthew Rossiter, Douglas N. Cogen and David K. Michaels of Fenwick & West LLP acted as legal advisor to DICE Therapeutics. For DICE, Centerview Partners LLC is acting as exclusive financial advisor and fairness opinion provider. DICE has agreed to pay Centerview an aggregate fee of approximately $44 million, $2 million of which was payable upon the rendering of Centerview’s opinion and approximately $42 million of which is payable contingent upon consummation of the Transactions. Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to Centerview in the transaction. Kirkland & Ellis LLP acted as due diligence provider to Lilly. Centerview Partners LLC acted as due diligence provider to DICE. Equiniti Trust Company acted transfer agent to DICE. Julia L. Minitti, Michael Hostetler and Uale Taotafa of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisors to DICE. Eli Lilly and Company (NYSE:LLY) completed the acquisition of DICE Therapeutics, Inc. (NasdaqGM:DICE) from a group of shareholders on August 9, 2023. DICE's common stock will be delisted from the NASDAQ Global Market.
お知らせ • Jun 21Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion.Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire DICE Therapeutics, Inc. (NasdaqGM:DICE) from RA Capital Healthcare Fund, L.P. and RA Capital Healthcare Fund, L.P., funds managed by RA Capital Management, L.P., J. Kevin Judice and others for $2.3 billion on June 18, 2023. Pursuant to the agreement, Eli Lilly and Company will commence a cash tender offer to purchase all of the outstanding shares of common stock of DICE Therapeutics at a price of $48 per share, net to the seller in cash, without interest, and subject to applicable withholding taxes. Following the successful closing of the tender offer, Lilly will acquire any shares of DICE that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer. Upon termination of the agreement under specified circumstances DICE Therapeutics may be required to pay Eli Lilly and Company a termination fee of $92 million. Consummation of the offer is subject to various conditions, including a majority of Shares then-outstanding being tendered in the offer and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The consummation of the Offer and Merger is not subject to a financing condition. The Board of Directors of DICE Therapeutics unanimously approved the transaction. The Board of Directors of Eli Lilly and Company approved the transaction. The transaction is expected to close in the third quarter of 2023. Michael P. Brueck and Chelsea N. Darnell of Kirkland & Ellis LLP acted as legal advisor to Eli Lilly and Company. Matthew Rossiter, Douglas N. Cogen and David K. Michaels of Fenwick & West LLP acted as legal advisor to DICE Therapeutics. For DICE, Centerview Partners LLC is acting as exclusive financial advisor and fairness opinion provider.
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$231m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (25% increase in shares outstanding).
Price Target Changed • Jun 21Price target decreased by 13% to US$56.30Down from US$64.43, the current price target is an average from 10 analysts. New target price is 21% above last closing price of US$46.44. Stock is up 217% over the past year. The company is forecast to post a net loss per share of US$2.57 next year compared to a net loss per share of US$2.13 last year.
分析記事 • May 14We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, DICE Therapeutics...
Recent Insider Transactions • Mar 22Independent Director recently sold US$291k worth of stockOn the 17th of March, James Scopa sold around 10k shares on-market at roughly US$29.05 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Feb 11DICE Therapeutics, Inc. Announces Board ChangesOn February 7, 2023, Shaan Gandhi, M.D., D. Phil., notified the Board of Directors of DICE Therapeutics, Inc. of his intent to resign as a Class I director of the Board, as the chair of the Nominating and Corporate Governance Committee of the Board and as a member of the Audit Committee of the Board, effective February 10, 2023. Such Resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company. In addition, the Board appointed Dr. Jake Simson, an existing member of the Board, to serve on the Audit Committee, effective upon the Resignation.
Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Mittie Doyle was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 12DICE Therapeutics, Inc. Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for PsoriasisDICE Therapeutics, Inc. announced positive topline data from its Phase 1 clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17. The trial was a first-in-human, randomized, double-blind, placebo-controlled study designed to generate safety and pharmacokinetic (PK) data in healthy volunteers as well as provide early clinical proof-of-concept in psoriasis patients. The trial was conducted in three overlapping parts: Phase 1a single ascending dose (SAD) (n=40); Phase 1b multiple ascending dose (MAD) (n=32); and Phase 1c proof-of-concept in psoriasis patients (n=32). Proof-of-concept achieved, supporting further development of DC-806 as potential best-in-class oral agent for psoriasis: The Phase 1c, placebo-controlled psoriasis portion enrolled a total of 8 patients in the high dose group (800 mg BID), 13 patients in the low dose group (200 mg BID), and 11 patients in the placebo group. Following 4 weeks of treatment, the mean percentage reduction in Psoriasis Area and Severity Index (PASI) from baseline was 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008. Reduction in PASI was an exploratory endpoint with no correction for multiplicity. Both doses of DC-806 shown to be biologically active via analysis of well-precedented biomarkers: Exploratory biomarker data demonstrated dose-dependent IL-17 target engagement, rapid onset of action, and pharmacodynamic effects consistent with direct inhibition of IL-17 signaling. DC-806 was well tolerated with an excellent safety profile across all dose groups: Data across all three cohorts showed DC-806 was well tolerated with a favorable safety profile in both healthy volunteers and psoriasis patients at all dose levels evaluated with no serious adverse events, no dose-limiting adverse events, no treatment-related discontinuations, and no clinically-significant changes in clinical and safety lab parameters (including liver enzymes). All treatment emergent adverse events (TEAEs) were classified as mild or moderate with no dose-dependent trend in the frequency, severity, or type of TEAEs observed. Robust PK profile and dose-dependent IL-17 target coverage: DC-806 showed a favorable PK profile with dose-proportional increases in serum concentrations throughout the study. Analysis of the MAD and Phase 1c data showed achievement of IC50 and IC90 coverage at trough with doses of 175 mg QD and 400 mg BID, respectively. DICE plans to advance DC-806 into a dose-ranging Phase 2b clinical trial in patients with moderate-to-severe psoriasis. The company plans to submit an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) in the first half of 2023 and initiate Phase 2b development.
Seeking Alpha • Oct 11DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higherTop-line results from a phase 1 trial of DICE Therapeutics' (NASDAQ:DICE) DC-806 for psoriasis showed the candidate met its proof-of-concept goal and was biologically active. Shares are up 71% in premarket trading. Data also showed DC-806 was well tolerated with an excellent safety profile. The placebo-controlled portion enrolled eight psoriasis patients in the high dose group (800 mg BID), 13 patients in the low dose group (200 mg BID), and 11 patients in the placebo group. After four weeks of treatment, the mean percentage reduction in Psoriasis Area and Severity Index from baseline was 43.7% in the high dose group compared to 13.3% in the placebo group. DICE (DICE) now plans to move DC-806, an oral IL-17 antagonist, into a dose-ranging phase 2b clinical trial. The company anticipates submitting an IND application with the US FDA in 1H 2023 and begin phase 2b at that time. Seeking Alpha's Quant Rating views DICE as a hold with high marks for growth and momentum.
分析記事 • Sep 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11DICE Therapeutics GAAP EPS of -$0.58DICE Therapeutics press release (NASDAQ:DICE): Q2 GAAP EPS of -$0.58. Cash, cash equivalents and marketable securities totaled $282.2 million at June 30, 2022. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milestones.
お知らせ • Jul 22DICE Therapeutics, Inc. Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806DICE Therapeutics, Inc. announced the completion of enrollment in the Company’s Phase 1 clinical trial of DC-806 in healthy volunteers and psoriasis patients. DC-806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of autoimmune and inflammatory diseases, including psoriasis. The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to generate safety and pharmacokinetic data and provide early clinical proof-of-concept in psoriasis patients. The trial is being conducted in three overlapping parts: Phase 1a (single ascending dose) and Phase 1b (multiple ascending dose) in healthy volunteers, and a Phase 1c (proof-of-concept) in psoriasis patients.
Seeking Alpha • Jul 18DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugsHC Wainwright has initiated coverage of DICE Therapeutics (NASDAQ:DICE) with a buy rating lauding the company's DELSCAPE technology platform aimed at creating new therapies against "difficult to target protein-protein interactions (PPIs), using small, targeted DNA-enabling libraries (DELs)." The firm has a $40 price target (~151% upside based on Friday's close). Analyst Emily Bodnar said that DELSCAPE can "identify selective binders by producing small, targeted DELs which has led to hundreds to tens of thousands of hits against difficult PPI targets." The company's lead candidate DC-806, a pill that targets IL-17, is being eyed for psoriasis. It is currently in phase 1. Bodnar conceded that although there are several IL-17-targeted biologics for psoriasis and related indications, there is only one approved that is a pill, Amgen's (AMGN) Otezla (apremilast). She noted that though Otezla has a PASI-75 score (efficacy) of only ~30%, the drug has more than $2B in annual sales. A full data readout from the phase 1 trial is expected this quarter, and if it is positive, the stock could see significant upside, Bodnar wrote.
お知らせ • Jun 26+ 1 more updateDICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 2000 Growth IndexDICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from Russell 2000 Growth Index
Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mittie Doyle was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 05High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Director Mittie Doyle was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 29DICE Therapeutics, Inc. Expands Management Team and Board of DirectorsDICE Therapeutics, Inc. announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE’s board of directors. Concurrently, Stephen Zachary, Ph.D., will be stepping down from the Company’s board. Mary Riley, J.D., as general counsel: Ms. Riley joins DICE following a 15-year tenure at Genentech, most recently serving as vice president, litigation, where she served on the legal leadership team and was responsible for managing a wide range of legal matters. She also previously led Genentech’s business law group and employment law group, where she served as a member of the human resources leadership team. Before joining Genentech, Mary was a partner at Heller Ehrman LLP and held roles at other corporate law firms. Mary received a J.D. Lisa Bowers, MHSA, to board of directors: Ms. Bowers is the chief commercial officer of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company founded to address a critical unmet need, the lack of therapeutic development in pediatric cancer. Prior to joining Day One, Lisa served as the chief executive officer and founder of Rhia Ventures. Mittie Doyle, M.D., FACR, to board of directors: Dr. Doyle is a proven research physician who has held numerous leadership roles in clinical development. She currently serves as chief medical officer of Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines. Prior to joining Aro, Dr. Doyle served as vice president, global therapeutic area head, immunology at CSL Behring.
Reported Earnings • Nov 15Third quarter 2021 earnings released: US$2.30 loss per shareThird quarter 2021 results: Net loss: US$17.3m (flat on 3Q 2020).
お知らせ • Sep 15DICE Therapeutics, Inc. has completed an IPO in the amount of $204 million.DICE Therapeutics, Inc. has completed an IPO in the amount of $204 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $17 Transaction Features: Sponsor Backed Offering